<DOC>
	<DOCNO>NCT02221960</DOCNO>
	<brief_summary>To evaluate MEDI6383 give alone together MEDI4736 adult subject recurrent metastatic solid tumor .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate MEDI6383 Alone Combination With MEDI4736 Adult Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , multicenter , open-label , dose-escalation , dose-expansion study evaluate safety , tolerability , pharmacokinetics , immunogenicity , pharmacodynamics , antitumor activity MEDI6383 alone combination MEDI4736 adult subject recurrent metastatic solid tumor .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female subject ; age ≥ 18 2 . Written informed consent must obtain 3 . Subjects must meet following criterion : 1 . Have recurrent metastatic solid tumor 2 . Must receive progressed , refractory , intolerant standard therapy appropriate specific tumor type . Subjects receive 5 prior line therapy recurrent metastatic disease include standard care investigational therapy 4 . Subjects must least 1 lesion 5 . Subjects must consent provide archived tumor specimen / tumor biopsy correlative biomarker study . 6 . Eastern Cooperative Oncology Group performance score 0 1 7 . In opinion invesgator likely complete ≥ 8 week treatment . 8 . Adequate organ function determine : . Absolute neutrophil count ≥ 1.5 x 109/L ( 1,500/mm3 ) ii.Platelet count ≥ 100 x 109/L ( 100,000/mm3 ) iii.Hemoglobin ≥ 9.0 g/dL within first 2 week prior first dose investigational product iv.Calculated creatinine clearance* ( CrCl ) 24 hour urine CrCl &gt; 50 mL/min v.Total bilirubin ≤ 1.5× ULN ; subject documented/suspected Gilbert 's disease , bilirubin ≤ 3× ULN vi.Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5× ULN vii.Serum Electrolytes within normal limit 9 . Females childbearing potential sexually active nonsterilized male partner must use 2 method highly effective contraception screening , must agree continue use precaution 90 day final dose investigational product ; 10 ) Nonsterilized male sexually active female partner childbearing potential must use highly effective method contraception Day 1 90 day receipt final dose investigational product 1 . Prior treatment TNFRSF agonists include OX40 , CD27 , CD137 ( 41BB ) , CD357 ( GITR ) . 2 . Subjects receive prior therapy regimens contain CTLA4 , PDL1 , PD1 antagonists NOT permit enroll unless follow apply : Must experience toxicity lead permanent discontinuation prior immunotherapy All AEs receive prior immunotherapy must resolve ≤ Grade 1 baseline prior screen study . 3 . Must experience ≥ Grade 3 AE neurologic ocular AE grade receive prior immunotherapy 4 . History severe allergic reaction unknown allergen component study drug formulation 5 . Active prior document autoimmune disease within past 2 year . 6 . Untreated central nervous system metastatic disease l 7 . Concurrent enrollment another clinical study , unless observational ( non interventional ) clinical study followup period interventional study 8 . Receipt anticancer therapy within 28 day prior first dose Investigational Product 9 . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment . 10 . Unresolved toxicity prior anticancer therapy 11 . Systemic anticoagulation daily aspirin dose exceed 325 mg per day 12 . Current prior use immunosuppressive medication within 14 day prior first dose MEDI6383 . ) 13 . History primary immunodeficiency , solid organ transplantation , tuberculosis 14 . True positive test result human immunodeficiency virus ( HIV ) hepatitis B C 15 . Receipt live , attenuated vaccine within 28 day prior first dose investigational product ) 16 . Pregnant breastfeed woman 17 . Major surgery ( define investigator ) within 4 week prior first dose MEDI6383 still recover prior surgery . Local surgery isolate lesion palliative intent acceptable 18 . Other invasive malignancy within 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Recurrent metastatic solid tumor , MEDI6383 , OX40</keyword>
</DOC>